The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
Condition: Idiopathic Juxtafoveal TelangiectasiaInterventions: Drug: zeaxanthin; Drug: zeaxanthinSponsor: Paul S. BernsteinActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 12, 2011 Category: Research Source Type: clinical trials
The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
Condition: Idiopathic Juxtafoveal TelangiectasiaInterventions: Drug: zeaxanthin; Drug: zeaxanthinSponsor: Paul S. BernsteinActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 12, 2011 Category: Research Source Type: clinical trials
The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)
Condition: Idiopathic Juxtafoveal TelangiectasiaInterventions: Drug: zeaxanthin; Drug: zeaxanthinSponsor: Paul S. BernsteinActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 12, 2011 Category: Research Source Type: clinical trials
Age-Related Eye Disease Study 2 (AREDS2)
Conditions: Age-related Macular Degeneration; CataractInterventions: Dietary Supplement: Lutein/zeaxanthin; Dietary Supplement: DHA/EPA; Drug: Lutein/zeaxanthin and DHA/EPASponsors: National Eye Institute (NEI); National Heart, Lung, and Blood Institute (NHLBI); Office of Dietary Supplements (ODS); National Center for Complementary and Integrative Health (NCCIH)Completed - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2006 Category: Research Source Type: clinical trials
